Spelling suggestions: "subject:"thyroid"" "subject:"thyroidectomy""
31 |
Mapeamento dúplex-Doppler colorido na avaliação da eficácia do Laser de baixa intensidade para o tratamento da tireoidite crônica autoimune: ensaio clínico randomizado placebo-controlado / Color Doppler ultrasonography in the evaluation of efficacy of the low-intensity Laser therapy of chronic autoimmune thyroiditis: placebo-controlled randomized clinical trialHöfling, Danilo Bianchini 16 February 2011 (has links)
INTRODUÇÂO: A tireoidite crônica autoimune (TCA) é a principal causa de hipotireoidismo adquirido, o qual requer tratamento contínuo com levotiroxina (LT4). Até o momento, não há terapia capaz de regenerar o tecido tireóideo lesado e melhorar sua função. Como a terapia com Laser de baixa intensidade (LILT) foi eficaz em outras doenças autoimunes, bem como na regeneração de vários tecidos, o objetivo deste estudo foi avaliar a eficácia do Laser de baixa intensidade no tratamento de pacientes com hipotireoidismo decorrente de tireoidite crônica autoimune utilizando-se os seguintes parâmetros de resposta: a) o mapeamento dúplex-Doppler colorido da tireoide; b) a função tireóidea estimada pela dose de LT4 necessária para manter as concentrações séricas de T3 total, T4 total, T4 livre e TSH normais; c) as concentrações séricas de anticorpos antiperoxidase tireóidea (TPOAb) e antitireoglobulina (TgAb). MÉTODOS: Trata-se de ensaio clínico randomizado, placebo-controlado, conduzido no Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, de março de 2006 a março de 2009, no qual foram incluídos 43 pacientes com hipotireoidismo causado por TCA. Todos eles apresentavam altas concentrações séricas de TPOAb e/ou TgAb e padrão ultrassonográfico compatível com TCA. Os pacientes foram randomizados em grupo L (submetido à LILT, n = 23) e P (submetido ao placebo, n = 20). Os limites da tireoide foram demarcados com o auxílio da ultrassonografia. Pacientes do grupo L submeteram-se à LILT (830 nm) e os do grupo P à função placebo do mesmo equipamento. Ambos os grupos foram submetidos, no total, à 10 sessões, duas vezes por semana, com a mesma técnica. Realizou-se pré e 30 dias pós-intervenção: o estudo ultrassonográfico (US) pelo modo-B, que incluiu o histograma computadorizado de escala de cinzas para estimar quantitativamente o índice de ecogenicidade; o US-Doppler colorido de amplitude atribuindo-se valores de 0 a 4 para os padrões de vascularização e o US-Doppler pulsado para estimar a velocidade de pico sistólico e o índice de resistividade das artérias tireóideas superiores e inferiores. Após o segundo US, os pacientes descontinuaram a LT4, a qual foi reintroduzida para os pacientes que apresentaram hipotireoidismo, em dose suficiente para obter normalização hormonal. Realizaram-se determinações séricas de T3 total, T4 total, T4 livre, TSH, TPOAb e TgAb pré-intervenção e no 1º, 2º, 3º, 6º e 9º meses pós-suspensão de LT4. RESULTADOS: No US modo-B pós-intervenção, verificou-se aumento estatisticamente significativo do índice de ecogenicidade no grupo L (1,24 ± 0,11) comparado ao P (0,98 ± 0,07; P < 0,001), assim como a proporção de pacientes com volume normal foi estatisticamente maior no grupo L (P = 0,005). O US-Doppler colorido de amplitude mostrou que o valor do padrão de vascularização foi estatisticamente maior no grupo P (2,3 ± 0,27) do que no L (1,87 ± 0,36; P = 0,033). Observou-se redução da dose de LT4 no grupo L (38,59 ± 20,22 g/dia) comparada à do P (106,88 ± 22,9 g/dia; p < 0,001). TPOAb foi menor no grupo L (681,91 ± 317,44 U/mL) do que no P (1176,40 ± 551,9 U/mL; p = 0,043). Não houve redução de TgAb e efeitos adversos. CONCLUSÕES: A LILT foi eficaz no tratamento da TCA, uma vez que no grupo L verificou-se: a) melhora da ecogenicidade, do volume e do padrão de vascularização da glândula tireoide no mapeamento dúplex-Doppler colorido; b) melhora da função da glândula tireoide, evidenciada pela redução da dose de LT4 necessária para tratar o hipotireoidismo c) modulação parcial da autoimunidade, demonstrada por meio da redução das concentrações séricas de TPOAb / INTRODUCTION: A chronic autoimmune thyroiditis (CAT) is the main cause of acquired hypothyroidism which requires continuous treatment with levothyroxine (LT4). So far there has been no such therapy which can make the damaged thyroid tissue regenerate, improving its function. As the low-intensity Laser therapy (LILT) was effective in other autoimmune diseases, as well as in regenerating several tissues, the objective of this study was to evaluate the efficacy of LILT in patients with hypothyroidism caused by CAT by utilizing the following response parameters: A) Color Doppler ultrasonography of thyroid; B) The thyroid function estimated by the dose of LT4 in order to keep the serum concentrations of normal T3, T4, free T4 (fT4) and TSH; C) The serum concentrations of thyroid peroxidase (TPOAb) and thyroglobulin antibodies (TgAb). METHODS: This is a placebo-controlled randomized clinical essay guided at the Institute of Radiology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo from March 2006 to March 2009, made up of 43 patients with hypothyroidism caused by CAT. All the patients showed high serum concentrations of TPOAb and/or TgAb and ultrasound pattern compatible with CAT. The patients were randomized in L group (submitted to LILT, n = 23) and P group (submitted to placebo, n = 20). The limits of thyroid were marked off with the help of ultrasonography. The patients in L group were submitted to LILT (830 nm) and the patients in P group were submitted to the placebo function of the same equipment. Both groups were submitted a total of 10 sessions, twice a week, using the same technique. Pre- and 30 days post-intervention were applied: ultrasonographic study (US) by B-mode, which included the grey scale computerized histogram to quantitatively estimate the index of echogenicity; the amplitude color Doppler US with values given from 0 to 4 for the vascularization patterns and the pulsed Doppler US to estimate the systolic peak velocity and the index of resistivity of superior and inferior thyroid arteries. After the second US the patients discontinued the LT4, which was later re-introduced in the patients having hypothyroidism in a certain amount so as to be sufficient to obtain hormonal normalization. Serum determinations of total T3, total T4, fT4, TSH, TPOAb and TgAb pre-intervention were accomplished and also in the 1st, 2nd, 3rd, 6th and 9th month post-suspension of LT4. RESULTS: In post-intervention B-mode US a significant increase in the index of echogenicity in L group (1.24 ± 0.11) was statistically observed compared with the P group (0.98 ± 0.07; P < 0.001), as well as the proportion of patients with normal volume was shown statistically higher in L group (P = 0.005). The amplitude color Doppler US showed the standard value of vascularization was statistically greater in P group (2.3 ± 0.27) than in L group (1.87 ± 0.36; P = 0.033). Pulsed Doppler US showed an increase in the systolic peak velocity of the inferior thyroid arteries in L group (34.47 ± 4.81 cm/s) in relation to P group (26.12 ± 4.29 cm/s; P = 0.016). A reduction in the dose of LT4 in L group (38.59 ± 20.22 g/day) was observed compared with the one in P group (106.88 ± 22.9 g/day; p < 0.001). TPOAb was smaller in L-group (681.91 ± 317.44 U/mL) than in P-group (1176.40 ± 551.9 U/mL; p = 0.043). There was no reduction of TgAb and adverse effects. CONCLUSIONS: LILT was effective in the treatment of CAT, once L group showed: A) amelioration of echogenicity, of volume and of vascularization of the thyroid gland in the color Doppler ultrasonography; B) improvement of thyroid function, featured through the reduction in the necessary dose of LT4 to treat the hypothyroidism; C) partial modulation of autoimmunity demonstrated by reduction of TPOAb serum concentrations
|
32 |
The role of secondary signaling in experimental autoimmune thyroiditisPeterson, Karin E. January 1998 (has links)
Thesis (Ph. D.)--University of Missouri--Columbia, 1998. / Typescript. Vita. Includes bibliographical references (leaves: 190-217). Also available on the Internet.
|
33 |
Maternal thyroid function during pregnancy:effects on pregnancy, peri- and neonatal outcome and on later maternal healthMännistö, T. (Tuija) 05 April 2011 (has links)
Abstract
Maternal thyroid dysfunction and/or antibodies are present in 5–10% of pregnancies and may be associated with increased risks of adverse pregnancy and perinatal outcomes. In the present study maternal thyroid function and antibody status in the Northern Finland Birth Cohort 1986 was analyzed using early pregnancy serum samples.
The impact of long-term storage on the stability of thyroid hormones and antibodies was studied and while TSH and thyroid hormone levels were not affected by storage time the concentrations of thyroid antibodies appeared to be significantly increased after 10 years of storage. Normal maternal thyroid function was evaluated by calculating thyroid hormone reference intervals in the thyroid antibody-negative population using a biobank of stored serum samples. Thyrotropin, free thyroxine and triiodothyronine reference intervals in the first and second trimester were 0.07–3.1 mU/L and 0.10–3.5 mU/L, 11.4–22.4 pmol/L and 11–18.9 pmol/L; and 3.4–7.0 pmol/L and 3.5–7.3 pmol/L, respectively, in this population (Abbott Architect method).
Compared with thyroid antibody-negative mothers, antibody-positive mothers had significantly higher TSH and lower fT4 concentrations and an increased risk of experiencing death of an infant in the perinatal period with odds ratios (ORs) of 3.1 (95% confidence interval 1.4–7.1) for thyroid-peroxidase and OR 2.6 (1.1–6.2) for thyroglobulin antibody positivity. These infants were more often born very preterm, which could possibly explain these increased risks. Positive thyroid antibody status was not associated with preterm birth in this study. No other major pregnancy or perinatal complications were observed among mothers or newborns of mothers with thyroid dysfunction/antibodies. Mothers, who had hypothyroidism or thyroid antibodies during pregnancy, had a very high risk of subsequent thyroid disease: hazard ratio (HR) 17.7 (7.8–40.6) for overt hypothyroidism, 4.2 (2.3–7.4) for thyroid-peroxidase and 3.3 (1.9–6.0) for thyroglobulin antibody positivity. Mothers with hypothyroidism during pregnancy had increased risk of subsequent diabetes, (HR 6.0 [2.2–16.4]).
Women at risk of thyroid dysfunction should be recognized and their prepregnancy counseling, blood sampling and treatment is probably beneficial. Whether universal screening of all pregnant women is justified is still under debate. / Tiivistelmä
Kilpirauhasen toimintahäiriö tai ainoastaan kilpirauhasvasta-aineita (tyreoideaperoksidaasi- tai tyreoglobuliinivasta-aineita) esiintyy 5–10 % raskaana olevista naisista ja ne mahdollisesti lisäävät riskiä raskausajan ja vastasyntyneisyyskauden ongelmiin. Tässä väitöskirjatyössä tutkittiin Pohjois-Suomen syntymäkohorttia vuodelta 1985–1986. Äitien kilpirauhasen toimintaa tutkittiin alkuraskauden verinäytteiden avulla. Selvitimme pitkäaikaisen (20 vuotta) pakkassäilytyksen vaikutusta kilpirauhaslaboratoriokokeisiin. Tutkimuksessamme pakkassäilytyksellä ei ollut vaikutusta kilpirauhashormonien pitoisuuksiin, mutta kilpirauhasvasta-aineiden pitoisuudet olivat merkittävästi lähtötasoa korkeampia 10 säilytysvuoden jälkeen. Äitien normaali kilpirauhasen toiminta arvioitiin laskemalla aineistosta kilpirauhashormonien viitevälit kilpirauhasvasta-ainenegatiivisille naisille raskauden ensimmäiselle ja toiselle kolmannekselle käyttäen Abbott Architect metodia. Viitearvot olivat: tyreotropiinille 0.07–3.1 mU/l ja 0.10–3.5 mU/l, vapaalle tyroksiinille 11.4–22.4 ja 11–18.9 pmol/l sekä vapaalle trijodotyroniinille 3.4–7.0 ja 3.5–7.3 pmol/l.
Äidin kilpirauhasen toimintahäiriöt eivät liittyneet vaikeisiin raskausajan tai vastasyntyneisyyskauden ongelmien, kuten ennenaikaisuuden ja kohtukuolemien esiintymiseen. Äidin kilpirauhasvasta-aineiden esiintyminen, mikä osoittaa kroonista autoimmuunityreoidiittia, lisäsi riskiä lapsen kohtukuolemaan ja ensimmäisen elinviikon kuolemaan; riski oli jopa kolminkertainen tyreoideaperoksidaasivasta-ainepositiivisten äitien vastasyntyneillä. Nämä vastasyntyneet olivat usein syntyneet hyvin ennenaikaisina (ennen 28. raskausviikkoa), mikä voi selittää tätä riskiä. Äidin kilpirauhasvasta-aineet eivät kuitenkaan lisänneet ennenaikaisten synnytysten riskiä tässä tutkimuksessa. Äideillä, joilla oli todettu kilpirauhasen vajaatoiminta tai kilpirauhasvasta-aineita, itsellään oli korkea, jopa 17-kertainen, riski sairastua myöhempiin kilpirauhasen sairauksiin, ja kilpirauhasen vajaatoiminta kuusinkertaisti sokeritautiin sairastumisriskin.
Olisi tärkeää tunnistaa jo ennen raskautta ne naiset, joilla on riski sairastua kilpirauhasen vajaatoimintaan. Raskauden aikaisesta yleisestä seulonnasta ei vielä ole yksimielisyyttä.
|
34 |
Alterações da PET-FDG na avaliação pré-operatória de pacientes com nódulos tireoidianos e correlação com marcadores imuno-histoquímicos / FDG PET abnormalities in preoperative evaluation of patients with thyroid nodules and association with immunohistochemical biomarkersSebastianes, Fernando Moreno 15 June 2011 (has links)
INTRODUÇÃO: Cerca de 80% dos nódulos de tireóide com citologia indeterminada são benignos. É possível que a tomografia por emissão de pósitrons (PET) com 2-[18F]- fluoro-2-desoxi-D-glicose (FDG) ajude a identificar quais dessas lesões são malignas. A captação de FDG depende da expressão de GLUTs (transportadores de glicose transmembrana) e hexoquinases. Captação difusa de FDG no leito tireoidiano tem ainda sido associada à tireoidite autoimune crônica (TAC), embora haja evidências de que pacientes com parênquima tireoidiano aparentemente sadio possam ter essa alteração. OBJETIVOS: (1) Determinar a sensibilidade e especificidade da PET-FDG no diagnóstico pré-operatório de malignidade dos nódulos tireoidianos, especialmente daqueles com resultados citológicos indeterminados, e avaliar esse desempenho no subgrupo de pacientes com TAC. (2) Determinar a correlação entre o achado de captação difusa tireoidiana da FDG à PET com o diagnóstico histopatológico de TAC e compará-la às concentrações plasmáticas dos anticorpos antitireoidianos. (3) Determinar a correlação entre a expressão dos marcadores imuno-histoquímicos GLUT 1, GLUT 3, GLUT 12, hexoquinase 2 e hexoquinase 3 com o diagnóstico histopatológico dos nódulos e com a captação de FDG apresentada pelos mesmos. MÉTODOS: 56 pacientes com nódulo de tireóide (42 com citologia indeterminada, 10 compatíveis com carcinoma papilífero e 4 com citologia benigna) realizaram PET-FDG e foram submetidos à tireoidectomia. Os resultados da PET-FDG foram comparados com o diagnóstico histopatológico do nódulo, com o infiltrado linfocitário no parênquima tireoidiano, com o diagnóstico de TAC e com os resultados do estudo imuno-histoquímico de micromatriz tecidual de tecido correspondente ao nódulo tireoidiano puncionado e ao tecido tireoidiano não nodular. RESULTADOS: 1) Todos os 21 pacientes com câncer de tireóide (11 com citologia indeterminada) apresentaram captação focal de FDG na tireóide. 2) Captação focal de FDG correlacionou-se com maior risco de malignidade (p<0,001). 3) Dos 31 pacientes com nódulos benignos com citologia indeterminada, 12 não tinham captação focal de FDG (especificidade de 39%). 4) Captação difusa no leito tireoidiano à PET-FDG foi associada à presença de TAC no exame histopatológico (p=0,019). Porém, 5 pacientes, sem sinais de infiltrado linfocitário, apresentaram captação difusa à PET-FDG. 5) Imunoexpressão dos anticorpos contra GLUTs 1, 3 e 12 e hexoquinases 2 e 3 nas células epiteliais dos nódulos não esteve positivamente associada com captação de FDG e com malignidade. 6) Não houve associação entre captação difusa de FDG no leito tireoidiano e imunoexpressão desses marcadores no parênquima tireoidiano não nodular. CONCLUSÕES: 1) A PET-FDG tem alta sensibilidade para diagnóstico de lesões malignas de tireóide, com especificidade de 39% para nódulos com citologia indeterminada. 2) Captação difusa de FDG no leito tireoidiano está associada à presença de TAC, mas pode ocorrer em pacientes sem infiltrado linfocitário. 3) A imuno-histoquímica para os anticorpos contra GLUTs 1, 3 e 12 e hexoquinases 2 e 3 não contribui para a diferenciação de nódulos malignos dos benignos e não se associa com a captação de FDG pelos nódulos / INTRODUCTION: Around 80% of thyroid nodules with indeterminate cytological result are benign. Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy- D-glucose (FDG) might help to identify malignant thyroid lesions. FDG uptake depends on GLUTs expression (transmembranous glucose transporters) and on hexokinases. Although diffuse FDG thyroid uptake has been associated with chronic autoimmune thyroiditis (CAT), there is some evidence that patients with apparently normal thyroid parenchyma can display this pattern of FDG uptake. OBJECTIVES: (1) To assess the sensitivity and specificity of FDG PET in identifying thyroid malignancy in the preoperative evaluation of thyroid nodules and evaluate these results in the subgroup of patients with indeterminate cytological results and in the subgroup with CAT. (2) To compare the finding of diffuse FDG thyroid uptake with the histopathologic diagnosis of CAT and with the serum levels of antithyroid antibodies. (3) To evaluate the immunoexpression by thyroid nodules of GLUT 1, GLUT 3, GLUT 12, hexokinase 2 and hexokinase 3 and to compare it with the histopathologic diagnosis of these nodules and with FDG uptake. METHODS: 56 patients with thyroid nodules (42 with indeterminate cytological result, 10 with papillary carcinoma and 4 with benign cytological result) underwent FDG PET and, subsequently, thyroidectomy. FDG PET results were compared with the histopathologic diagnosis of the nodule, lymphocytic infiltrate of thyroid parenchyma, CAT diagnosis and immunohistochemical results of tissue microarray of the tissue from the thyroid nodule and the normal thyroid parenchyma. RESULTS: 1) All the 21 patients with thyroid cancer (11 with indeterminate cytological result) had focal thyroid FDG uptake. 2) Focal FDG uptake was associated with malignancy (p<0.001). 3) From 31 patients with benign nodules whose cytological result was indeterminate, 12 did not display focal FDG uptake (specificity of 39%). 4) Diffuse FDG uptake in thyroid bed was associated with CAT in the histopathologic exam (p=0.019). However, 5 patients without lymphocytic infiltrate had diffuse FDG uptake. 5) Immunoexpression of GLUTs 1, 3 and 12 and hexokinases 2 and 3 by epithelial cells of thyroid nodules was not positively associated with FDG uptake and malignancy. 6) There was no association between diffuse FDG uptake in thyroid bed and immunoexpression of these markers in the normal thyroid tissue. CONCLUSIONS: 1) FDG PET has high sensitivity to the diagnosis of malignancy in thyroid bed, with a specificity of 39% for thyroid nodules with indeterminate cytological result. 2) Diffuse FDG uptake in the thyroid bed is associated with CAT, but can be found in patients without lymphocytic infiltrate. 3) Immunohystochemistry against GLUTs 1, 3 and 12 and hexokinases 2 and 3 does not add in the differentiation of malignant and benign thyroid nodules and is not associated with FDG uptake by these nodules
|
35 |
Assoziation der Autoimmunthyreoiditis mit depressiven Störungen / Association of autoimmune thyroiditis with depressive disordersHaust, Merle 20 March 2012 (has links)
No description available.
|
36 |
Kan selentillskott behandla autoimmun tyreoidit? : En litteraturstudie / Could selenium supplementation treat autoimmune thyroiditis? : A litterature studyLidén, Pauline January 2018 (has links)
Introduktion. Autoimmun tyreoidit (AITD) är en kronisk autoimmun sjukdom där immunförsvarets antikroppar (ab) attackerar tyreoideaproteinerna tyreoideaperoxidas (TPO) och/eller tyreoglobulin (TG). Studier visar att selentillskott hos patienter med AITD kan minska tyreoideaantikroppar, storleken och antalet noduler hos en förstorad tyreoidea. Syftet med detta arbete var att undersöka hur selentillskott påverkar serumnivåer av TPOab, samt tyreoideahormonnivåer vid AITD. Metod. Arbetet är en litteraturstudie och därför har metoden varit att samla relevant litteratur genom PubMed med sökningar som ”selenium autoimmune thyroiditis”, ”selenium thyroid” och ”autoimmune thyroiditis”. Bland sökresultaten valdes nio artiklar ut baserat på studiekvalitet, publikationsår och relevans. Bland artiklarna granskades och sammanställdes uppmätta nivåer av TPOab samt tyreoideahormonnivåer, vilka valdes som indikation på effekt utav selentillskott. Resultat. Resultaten var inkonsekventa. Majoriteten av studierna (7 av 9) tydde på att oral administrering av selentillskott effektivt minskade serumkoncentrationerna av TPOab hos patienter med AITD i alla åldersgrupper. De studier som resulterade i störst minskning av TPOab pågick i 3-12 månader. Utav de 9 studerade artiklarna var det endast en studie som inte rapporterade någon som helst positiv klinisk effekt hos patienterna. Två av studierna visade att selen förhindrar vidare försämring av tyreoideans ekogenitet, vilket tyder på att selen kan hejda inflammationsprocessen men ej reversera tyreoideaskadorna den orsakat. Majoriteten av studierna (7 av 9) visade att selentillskott ej ger några signifikanta förändringar i tyreoideahormonerna: TSH, fT4 och fT3. Diskussion. Varför AITD-patienter svarar olika på selenadministrering är ännu okänt, men kan misstänkas bero på selenbehandlingens varaktighet, patienternas intratyroidnivåer av selen vid studiens början, förekomst av jodbrist, samt patienternas ålder och sjukdomsprogression. Slutsats. Att ha adekvata fysiologiska nivåer av selen är av stor vikt för att bevara tyreoideans hälsa och förebygga tyreoidearelaterade sjukdomar. Majoriteten utav de granskade studierna visar att tillskott av selen kan minska antalet TPOab. Selentillskott kan även ha immunrelaterade fördelar men verkar inte påverka nivån tyreoideahormonnivåer. Inga negativa effekter påvisades vid intag av selentillskott vilket gör dess administrering säker. Fler studier behöver dock göras för att fastställa effektiviteten av selentillskott vid AITD. / Introduction. Autoimmune thyroiditis (AITD) is a chronic autoimmune disease in which the immune system's antibodies (ab) attack the thyroid proteins thyroid peroxidase (TPO) and/or thyroglobulin (TG). Studies show that selenium supplementation in patients with AITD can reduce thyroid antibodies and the size and number of nodules in an enlarged thyroid. The purpose of this study was to investigate how selenium supplementation affects the serum levels of thyroid peroxidase antibodies (TPOab) and thyroid hormone levels in autoimmune thyroiditis. Method. This is a literature study and therefore the method has been to gather relevant literature through searches on PubMed such as "selenium autoimmune thyroiditis", "selenium thyroid" and "autoimmune thyroiditis". Among the search results, nine articles were selected based on quality, publication year and relevance. Among the articles, measured levels of TPOab and thyroid hormone levels were examined and compiled, and were chosen as an indication of the effect of selenium supplementation. Results. The results were inconsistent. The majority of the studies (7 of 9) suggest that oral administration of selenium supplements effectively reduced serum concentrations of TPOab in patients with AITD in all age groups. The studies that resulted in the largest decrease in TPOab lasted for 3-12 months. Out of the 9 examined studies, only one study did not report any positive clinical effect in patients. Two of the studies showed that the selenium prevents further impairment of thyroid echogenicity, suggesting that selenium can inhibit the inflammatory process but not reverse the pre-existing thyroid damage it’s caused. The majority of studies (7 out of 9) show that selenium supplementation does not produce significant changes in the thyroid hormones: TSH, fT4 and fT3. Discussion. Why AITD-patients respond differently to selenium administration is still unknown, but it may be due to the duration of selenium treatment, the patients' intrathyroid levels of selenium at the onset of the study, the presence of iodine deficiency, as well as the age and disease progression of the patients. Conclusion. Having adequate physiological levels of selenium is of great importance in preserving thyroid health and preventing thyroid-related diseases. The majority of the studies show that selenium supplementation can reduce the number of TPOab. Selenium supplementation may also have immune related benefits but does not appear to affect the thyroid hormone levels. No adverse effects were observed during selenium supplementation, which makes its administration safe. However, more studies are needed to determine the effectiveness of selenium supplementation for AITD.
|
37 |
Alterações da PET-FDG na avaliação pré-operatória de pacientes com nódulos tireoidianos e correlação com marcadores imuno-histoquímicos / FDG PET abnormalities in preoperative evaluation of patients with thyroid nodules and association with immunohistochemical biomarkersFernando Moreno Sebastianes 15 June 2011 (has links)
INTRODUÇÃO: Cerca de 80% dos nódulos de tireóide com citologia indeterminada são benignos. É possível que a tomografia por emissão de pósitrons (PET) com 2-[18F]- fluoro-2-desoxi-D-glicose (FDG) ajude a identificar quais dessas lesões são malignas. A captação de FDG depende da expressão de GLUTs (transportadores de glicose transmembrana) e hexoquinases. Captação difusa de FDG no leito tireoidiano tem ainda sido associada à tireoidite autoimune crônica (TAC), embora haja evidências de que pacientes com parênquima tireoidiano aparentemente sadio possam ter essa alteração. OBJETIVOS: (1) Determinar a sensibilidade e especificidade da PET-FDG no diagnóstico pré-operatório de malignidade dos nódulos tireoidianos, especialmente daqueles com resultados citológicos indeterminados, e avaliar esse desempenho no subgrupo de pacientes com TAC. (2) Determinar a correlação entre o achado de captação difusa tireoidiana da FDG à PET com o diagnóstico histopatológico de TAC e compará-la às concentrações plasmáticas dos anticorpos antitireoidianos. (3) Determinar a correlação entre a expressão dos marcadores imuno-histoquímicos GLUT 1, GLUT 3, GLUT 12, hexoquinase 2 e hexoquinase 3 com o diagnóstico histopatológico dos nódulos e com a captação de FDG apresentada pelos mesmos. MÉTODOS: 56 pacientes com nódulo de tireóide (42 com citologia indeterminada, 10 compatíveis com carcinoma papilífero e 4 com citologia benigna) realizaram PET-FDG e foram submetidos à tireoidectomia. Os resultados da PET-FDG foram comparados com o diagnóstico histopatológico do nódulo, com o infiltrado linfocitário no parênquima tireoidiano, com o diagnóstico de TAC e com os resultados do estudo imuno-histoquímico de micromatriz tecidual de tecido correspondente ao nódulo tireoidiano puncionado e ao tecido tireoidiano não nodular. RESULTADOS: 1) Todos os 21 pacientes com câncer de tireóide (11 com citologia indeterminada) apresentaram captação focal de FDG na tireóide. 2) Captação focal de FDG correlacionou-se com maior risco de malignidade (p<0,001). 3) Dos 31 pacientes com nódulos benignos com citologia indeterminada, 12 não tinham captação focal de FDG (especificidade de 39%). 4) Captação difusa no leito tireoidiano à PET-FDG foi associada à presença de TAC no exame histopatológico (p=0,019). Porém, 5 pacientes, sem sinais de infiltrado linfocitário, apresentaram captação difusa à PET-FDG. 5) Imunoexpressão dos anticorpos contra GLUTs 1, 3 e 12 e hexoquinases 2 e 3 nas células epiteliais dos nódulos não esteve positivamente associada com captação de FDG e com malignidade. 6) Não houve associação entre captação difusa de FDG no leito tireoidiano e imunoexpressão desses marcadores no parênquima tireoidiano não nodular. CONCLUSÕES: 1) A PET-FDG tem alta sensibilidade para diagnóstico de lesões malignas de tireóide, com especificidade de 39% para nódulos com citologia indeterminada. 2) Captação difusa de FDG no leito tireoidiano está associada à presença de TAC, mas pode ocorrer em pacientes sem infiltrado linfocitário. 3) A imuno-histoquímica para os anticorpos contra GLUTs 1, 3 e 12 e hexoquinases 2 e 3 não contribui para a diferenciação de nódulos malignos dos benignos e não se associa com a captação de FDG pelos nódulos / INTRODUCTION: Around 80% of thyroid nodules with indeterminate cytological result are benign. Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy- D-glucose (FDG) might help to identify malignant thyroid lesions. FDG uptake depends on GLUTs expression (transmembranous glucose transporters) and on hexokinases. Although diffuse FDG thyroid uptake has been associated with chronic autoimmune thyroiditis (CAT), there is some evidence that patients with apparently normal thyroid parenchyma can display this pattern of FDG uptake. OBJECTIVES: (1) To assess the sensitivity and specificity of FDG PET in identifying thyroid malignancy in the preoperative evaluation of thyroid nodules and evaluate these results in the subgroup of patients with indeterminate cytological results and in the subgroup with CAT. (2) To compare the finding of diffuse FDG thyroid uptake with the histopathologic diagnosis of CAT and with the serum levels of antithyroid antibodies. (3) To evaluate the immunoexpression by thyroid nodules of GLUT 1, GLUT 3, GLUT 12, hexokinase 2 and hexokinase 3 and to compare it with the histopathologic diagnosis of these nodules and with FDG uptake. METHODS: 56 patients with thyroid nodules (42 with indeterminate cytological result, 10 with papillary carcinoma and 4 with benign cytological result) underwent FDG PET and, subsequently, thyroidectomy. FDG PET results were compared with the histopathologic diagnosis of the nodule, lymphocytic infiltrate of thyroid parenchyma, CAT diagnosis and immunohistochemical results of tissue microarray of the tissue from the thyroid nodule and the normal thyroid parenchyma. RESULTS: 1) All the 21 patients with thyroid cancer (11 with indeterminate cytological result) had focal thyroid FDG uptake. 2) Focal FDG uptake was associated with malignancy (p<0.001). 3) From 31 patients with benign nodules whose cytological result was indeterminate, 12 did not display focal FDG uptake (specificity of 39%). 4) Diffuse FDG uptake in thyroid bed was associated with CAT in the histopathologic exam (p=0.019). However, 5 patients without lymphocytic infiltrate had diffuse FDG uptake. 5) Immunoexpression of GLUTs 1, 3 and 12 and hexokinases 2 and 3 by epithelial cells of thyroid nodules was not positively associated with FDG uptake and malignancy. 6) There was no association between diffuse FDG uptake in thyroid bed and immunoexpression of these markers in the normal thyroid tissue. CONCLUSIONS: 1) FDG PET has high sensitivity to the diagnosis of malignancy in thyroid bed, with a specificity of 39% for thyroid nodules with indeterminate cytological result. 2) Diffuse FDG uptake in the thyroid bed is associated with CAT, but can be found in patients without lymphocytic infiltrate. 3) Immunohystochemistry against GLUTs 1, 3 and 12 and hexokinases 2 and 3 does not add in the differentiation of malignant and benign thyroid nodules and is not associated with FDG uptake by these nodules
|
Page generated in 0.0618 seconds